Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Acquires $15,175.92 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Andrew Cittadine purchased 20,508 shares of Monopar Therapeutics stock in a transaction that occurred on Thursday, June 20th. The stock was purchased at an average cost of $0.74 per share, for a total transaction of $15,175.92. Following the completion of the purchase, the chief operating officer now owns 186,132 shares of the company’s stock, valued at $137,737.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Andrew Cittadine also recently made the following trade(s):

• On Monday, June 17th, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $10,800.00.
• On Thursday, June 13th, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average cost of $0.91 per share, for a total transaction of $10,920.00.
• On Monday, June 3rd, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average cost of $0.76 per share, for a total transaction of $9,120.00.
• On Friday, May 31st, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $7,680.00.
• On Wednesday, May 29th, Andrew Cittadine bought 12,000 shares of Monopar Therapeutics stock. The stock was bought at an average cost of $0.64 per share, for a total transaction of $7,680.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $0.72 on Monday. The company has a market cap of $12.55 million, a P/E ratio of -1.33 and a beta of 1.15. Monopar Therapeutics Inc. has a 1 year low of $0.27 and a 1 year high of $1.73. The stock’s fifty day moving average price is $0.71 and its 200-day moving average price is $0.61.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. On average, sell-side analysts anticipate that Monopar Therapeutics Inc. will post -0.37 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on MNPR. Jonestrading raised Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday, April 11th. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Monopar Therapeutics in a report on Friday, May 10th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.